These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25903922)

  • 1. Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir.
    Fagone P; Mangano K; Quattrocchi C; Cavalli E; Mammana S; Lombardo GA; Pennisi V; Zocca MB; He M; Al-Abed Y; Nicoletti F
    Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):306-15. PubMed ID: 25903922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis.
    Abou-El-Naga IF; El Kerdany ED; Mady RF; Shalaby TI; Zaytoun EM
    Parasitol Int; 2017 Dec; 66(6):735-747. PubMed ID: 28838776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
    Capel E; Auclair M; Caron-Debarle M; Capeau J
    Antivir Ther; 2012; 17(3):549-56. PubMed ID: 22293506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.
    Auclair M; Afonso P; Capel E; Caron-Debarle M; Capeau J
    Antivir Ther; 2014; 19(8):773-82. PubMed ID: 24535489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.
    Lan X; Kiyota T; Hanamsagar R; Huang Y; Andrews S; Peng H; Zheng JC; Swindells S; Carlson GA; Ikezu T
    J Neuroimmune Pharmacol; 2012 Jun; 7(2):412-23. PubMed ID: 21826404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells.
    Basile MS; Mazzon E; Krajnovic T; Draca D; Cavalli E; Al-Abed Y; Bramanti P; Nicoletti F; Mijatovic S; Maksimovic-Ivanic D
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30261624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
    Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
    Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of two HIV protease inhibitors, Saquinavir and Ritonavir, on lymphocytes from healthy seronegative individuals.
    Delmonte OM; Bertolotto G; Ricotti E; Tovo PA
    Immunol Lett; 2007 Aug; 111(2):111-5. PubMed ID: 17659786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV Protease Inhibitors Apoptotic Effect in SH-SY5Y Neuronal Cell Line.
    Tricarico PM; de Oliveira Franca RF; Pacor S; Ceglia V; Crovella S; Celsi F
    Cell Physiol Biochem; 2016; 39(4):1463-70. PubMed ID: 27607424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.
    Janneh O; Bray PG; Jones E; Wyen C; Chiba P; Back DJ; Khoo SH
    J Antimicrob Chemother; 2010 May; 65(5):906-16. PubMed ID: 20237075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis.
    Alvarenga DLR; Silva AHDS; Fiuza JA; Gaze ST; de Oliveira JG; Oliveira RC; Calzavara-Silva CE; Pascoal-Xavier MA; Alves ÉAR
    Int Immunopharmacol; 2018 Jul; 60():179-188. PubMed ID: 29747123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
    Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
    AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry.
    Rouzes A; Berthoin K; Xuereb F; Djabarouti S; Pellegrin I; Pellegrin JL; Coupet AC; Augagneur S; Budzinski H; Saux MC; Breilh D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):209-16. PubMed ID: 15556535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.
    Hellinger J; Cohen C; Morris A; Sheble-Hall S; Gordon D; Foy C; Jackson-Pope L; Shevitz A; van Schaic E
    HIV Clin Trials; 2005; 6(2):107-17. PubMed ID: 15983895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartic peptidase of
    Granato MQ; Sousa IS; Rosa TLSA; Gonçalves DS; Seabra SH; Alviano DS; Pessolani MCV; Santos ALS; Kneipp LF
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):629-638. PubMed ID: 32037904
    [No Abstract]   [Full Text] [Related]  

  • 17. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells.
    Diker B; Janneh O; van Heeswijk RP; Copeland KF
    Drug Metab Lett; 2010 Dec; 4(4):241-5. PubMed ID: 20690898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.